Related references
Note: Only part of the references are listed.An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases
Antoine Vanier et al.
RHEUMATOLOGY (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis
R van Vollenhoven et al.
RHEUMATOLOGY (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials
Josef Smolen et al.
ARTHRITIS RESEARCH & THERAPY (2019)
EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effectiveness of methotrexate with step-down glucocorticoid remission induction ( COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial
Patrick Verschueren et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study
J. van den Hoek et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
Unraveling Patient-Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study
Kristien van der Elst et al.
ARTHRITIS CARE & RESEARCH (2016)
Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study
Cristiano S. Moura et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
Diego Kyburz et al.
RHEUMATOLOGY (2011)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
Paul Emery et al.
LANCET (2008)
Share Paper
